UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 3,196,919 Shares of Bristol-Myers Squibb (NYSE:BMY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Bristol-Myers Squibb (NYSE:BMY) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,271,742 shares of the biopharmaceutical company’s stock after acquiring an additional 3,196,919 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.10% of Bristol-Myers Squibb worth $1,259,690,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Merit Financial Group LLC grew its holdings in Bristol-Myers Squibb by 34.1% during the fourth quarter. Merit Financial Group LLC now owns 42,435 shares of the biopharmaceutical company’s stock worth $2,400,000 after acquiring an additional 10,796 shares during the period. Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 9.4% during the 4th quarter. Ameritas Advisory Services LLC now owns 15,807 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 1,357 shares during the last quarter. Krilogy Financial LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $570,000. Grove Bank & Trust grew its stake in shares of Bristol-Myers Squibb by 14.9% in the fourth quarter. Grove Bank & Trust now owns 18,550 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 2,407 shares in the last quarter. Finally, Annex Advisory Services LLC grew its stake in shares of Bristol-Myers Squibb by 6.0% in the fourth quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 384 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 1.0%

Shares of Bristol-Myers Squibb stock opened at $47.22 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business’s 50 day moving average is $52.80 and its 200-day moving average is $55.94. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The stock has a market cap of $96.10 billion, a P/E ratio of -10.68, a P/E/G ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same period in the prior year, the firm earned ($4.40) EPS. The business’s revenue was down 5.6% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.25%. Bristol-Myers Squibb’s dividend payout ratio is presently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat purchased 4,250 shares of the business’s stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BMY shares. Jefferies Financial Group cut their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Citigroup increased their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, Argus raised Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.